1 not yet recruiting, 1 recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Higher-risk Myelodysplastic Syndrome: new trials by email Literature Review of Higher-risk Myelodysplastic Syndrome trials Research Report on Higher-risk Myelodysplastic Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AZA+Lus VS AZA Monotherapy in HR-MDS Azacitidine (AZA), Luspatercept - Higher-risk Myelodysplastic Syndrome | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 86 | 2025-04-01 | 2025-04-15 |
| Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4). Lisaftoclax (APG-2575), Azacitidine Injection, Placebo - Higher-risk Myelodysplastic Syndrome | Phase 3 | Recruiting | Ascentage Pharma Group Inc. | 490 | 2025-01-22 | 2026-10-13 |
Azacitidine (2) · Lisaftoclax (1) · luspatercept (1)
Ascentage Pharma Group Inc. (1) · Peking Union Medical College Hospital (1)
Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Norway (1) · Poland (1) · Spain (1)
Guillermo Garcia-Manero, M.D. (1) · Xiaojun Huang, M.D., Ph.D. (1)